AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis

AbbVie Inc ABBV announced new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating Skyrizi (risankizumab) in adults with active psoriatic arthritis for one year (52 weeks).
The results were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.
The new long-term data showed that 70% and 58% of patients initially treated with risankizumab achieved American College of Rheumatology 20 (ACR20) response in KEEPsAKE-1 and KEEPsAKE-2 respectively at one year.
Among patients initially treated with risankizumab, 43% in KEEPsAKE-1 and 32% in KEEPsAKE-2 achieved ACR50 response, and 26% in KEEPsAKE-1 and 17% in KEEPsAKE-2 achieved ACR70 response at one year.
At one year, 68% and 64% of patients achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) in KEEPsAKE-1 and KEEPsAKE-2, respectively.
Price Action: ABBV stock is up 0.06% at $108.91 during the market session on the last check Thursday.